Diabetes Care After Transplant: Definitions, Risk Factors, and Clinical Management

Medical Clinics of North America

Volumn 100, Issue 3, 2016, Pages 535-550

  Wallia, Amisha ^a   Illuri, Vidhya ^a   Molitch, Mark E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Diabetes; Immunosuppression; Insulin; Kidney; Liver; NODAT; Transplant; Transplantation

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALBIGLUTIDE; ALOGLIPTIN; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BELATACEPT; BIGUANIDE DERIVATIVE; CALCINEURIN INHIBITOR; CANAGLIFLOZIN; CORTICOSTEROID; CYTOCHROME P450 3A4; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DULAGLUTIDE; GLIBENCLAMIDE; GLINIDE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; IMMUNOSUPPRESSIVE AGENT; INSULIN; LIRAGLUTIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

COMORBIDITY; DIABETES CARE; DIABETES MELLITUS; DRUG INTERACTION; DRUG METABOLISM; GLYCEMIC CONTROL; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; NEW ONSET DIABETES AFTER TRANSPLANTATION; OUTPATIENT CARE; PATIENT CARE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; TRANSIENT POSTOPERATIVE HYPERGLYCEMIA; AFTERCARE; CASE REPORT; HOSPITAL DISCHARGE; HYPERGLYCEMIA; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RISK FACTOR;

AFTERCARE; DIABETES MELLITUS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; INFUSIONS, INTRAVENOUS; INSULIN; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; PATIENT DISCHARGE; POSTOPERATIVE COMPLICATIONS; RISK FACTORS;

EID: 84961221272     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2016.01.005     Document Type: Review

References (101)

1. Yeh C.-C., Yang H.-R., Liao C.-C., et al. Adverse outcomes after noncardiac surgery in patients with diabetes: a nation-wide population-based retrospective study. Diabetes Care 2013, 36(10):3216-3221.
2. Montori V.M., Basu A., Erwin P.J., et al. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 2002, 25(3):583-592.
3. Davidson J., Wilkinson A., Dantal J., et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003, 75(10 Suppl):SS3-S24.
4. Van den Berghe G., Wouters P., Weekers F., et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001, 345(19):1359-1367.
5. Finfer S., Chittock D.R., Su S.Y., et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009, 360(13):1283-1297.
6. Preiser J.C., Devos P., Ruiz-Santana S., et al. Prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. Intensive Care Med 2009, 35:1738-1748.
7. Ammori J.B., Sigakis M., Englesbe M.J., et al. Effect of intraoperative hyperglycemia during liver transplantation. J Surg Res 2007, 140(2):227-233.
8. Thomas M.C., Mathew T.H., Russ G.R., et al. Early peri-operative glycaemic control and allograft rejection in patients with diabetes mellitus: a pilot study. Transplantation 2001, 72(7):1321-1324.
9. Thomas M.C., Moran J., Mathew T.H., et al. Early peri-operative hyperglycaemia and renal allograft rejection in patients without diabetes. BMC Nephrol 2000, 1:1.
10. Wallia A., Parikh N.D., Molitch M.E., et al. Posttransplant hyperglycemia is associated with increased risk of liver allograft rejection. Transplantation 2010, 89(2):222-226.
11. Hermayer K.L., Egidi M.F., Finch N.J., et al. A randomized controlled trial to evaluate the effect of glycemic control on renal transplantation outcomes. J Clin Endocrinol Metab 2012, 97(12):4399-4406.
12. Ramirez S.C., Maaske J., Kim Y., et al. The association between glycemic control and clinical outcomes after kidney transplantation. Endocr Pract 2014, 20(9):894-900.
13. Wallia A., Parikh N.D., O'Shea-Mahler E., et al. Glycemic control by a glucose management service and infection rates following liver transplantation. Endocr Pract 2011, 17(4):546-551.
14. Finfer S., Liu B., Chittock D.R., et al. Hypoglycemia and risk of death in critically ill patients. N Engl J Med 2012, 367(12):1108-1118.
15. Moghissi E.S., Korytkowski M.T., DiNardo M., et al. American Association of Clinical Endocrinologists and American Diabetes Association Consensus statement on inpatient glycemic control. Diabetes Care 2009, 32(6):1119-1131.
16. Ong M.S., Coiera E. A systematic review of failures in handoff communication during intrahospital transfers. Jt Comm J Qual Patient Saf 2011, 37(6):274-284.
17. Wallia A., Molitch M.E. Insulin therapy for type 2 diabetes mellitus. JAMA 2014, 311:2315-2325.
18. Ganji M.R., Charkhchian M., Hakemi M., et al. Association of hyperglycemia on allograft function in the early period after renal transplantation. Transplant Proc 2007, 39(4):852-854.
19. Hosseini M.S., Nemati E., Pourfarziani V., et al. Early hyperglycemia after allogenic kidney transplantation: does it induce infections. Ann Transplant 2007, 12(4):23-26.
20. Cosio F.G., Pesavento T.E., Kim S., et al. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int 2002, 62(4):1440-1446.
21. Woodward R.S., Schnitzler M.A., Baty J., et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003, 3(5):590-598.
22. Sharif A., Hecking A., deVries A.P.J., et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am J Transplant 2014, 14:1992-2000.
23. American Diabetes Association Standards of medical care in diabetes-2016. Diabetes Care 2016, 39(Suppl 1):S1-S112.
24. Van Raalte D.H., Ouwens D.M., Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options?. Eur J Clin Invest 2009, 39(2):81-93.
25. Hecking M., Werzowa J., Haidinger M., for the European-New-Onset Diabetes after Transplantation Working Group, et al. Novel views on new-onset diabetes after transplantation: development, prevention and treatment. Nephrol Dial Transplant 2013, 28:550-566.
26. Markell M. New-onset diabetes mellitus in transplant patients: pathogenesis, complications, and management. Am J Kidney Dis 2004, 43(6):953-965.
27. Baid S., Cosimi A.B., Farrell M.L., et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001, 72(6):1066-1072.
28. Bloom R.D., Rao V., Weng F., et al. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 2002, 13(5):1374-1380.
29. Yadav A.D., Chang Y.-U., Aqel B.A., et al. New onset diabetes mellitus in living donor versus deceased donor liver transplant recipients: analysis of the UNOS/OPTN Database. J Transplant 2013, 2013:269096.
30. Hjelmesaeth J., Hartmann A., Kofstad J., et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997, 64(7):979-983.
31. Rostambeigi N., Lanza I.R., Dzeja P.P., et al. Unique cellular and mitochondrial defects mediate FK506-induced islet beta-cell dysfunction. Transplantation 2011, 91(6):615-623.
32. Heisel O., Heisel R., Balshaw R., et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004, 4(4):583-595.
33. Vincenti F., Jensik S.C., Filo R.S., et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002, 73(5):775-782.
34. Vincenti F., Friman S., Scheuermann E., et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007, 7:1506-1514. on the behalf of the DIRECT (Diabetes Incidence after Renal Transplantation: Neoral C2 Monitoring Versus Tacrolimus) Investigators.
35. Xu X., Ling Q., He Z.L., et al. Post-transplant diabetes mellitus in liver transplantation: Hangzhou experience. Hepatobiliary Pancreat Dis Int 2008, 7(5):465-470.
36. Ghisdal L., Bouchta N.B., Broeders N., et al. Conversion from tacrolimus to cyclosporine A for new-onset diabetes after transplantation: a single-centre experience in renal transplanted patients and review of the literature. Transpl Int 2008, 21(2):146-151.
37. Barlow A.D., Nicholson M.L., Herbert T.P. Evidence for rapamycin toxicity in pancreatic β-cells and a review of the underlying molecular mechanisms. Diabetes 2013, 62(8):2674-2682.
38. Araki M., Flechner S.M., Ismail H.R., et al. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs. Transplantation 2006, 81(3):335-341.
39. Murakami N., Riella L.V., Funakoshi T. Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis. Am J Transplant 2014, 14:2317-2327.
40. Su V.C., Harrison J., Rogers C., et al. Belatacept: a new biologic and its role in kidney transplantation. Ann Pharmacother 2012, 46(1):57-67.
41. Masson P., Henderson L., Chapman J.R., et al. Belatacept for kidney transplant recipients. Cochrane Database Syst Rev 2014, (11). CD010699.
42. Klintmalm G.B., Feng S., Lake J.R., et al. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized Study. Am J Transplant 2014, 14:1817-1827.
43. Umpierrez G.E., Reyes D., Smiley D., et al. Hospital discharge algorithm based on admission HbA1c for the management of patients with type 2 diabetes. Diabetes Care 2014, 37(11):2934-2939.
44. Inzucchi S.E., Bergenstal R.M., Buse J.B., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35(6):1364-1379.
45. Inzucchi S.E., Bergenstal R.M., Buse J.B., et al. Management of hyperglycemia in type 2 diabetes 2015: a patient centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015, 38:140-149.
46. Chakkera H.A., Pomeroy J., Weil E.J., et al. Can new-onset diabetes after kidney transplant be prevented?. Diabetes Care 2013, 36:1406-1412.
47. Ghisdal L., Vanholder R., Van Laecke S., et al. New-onset diabetes after renal transplantation. Risk assessment and management. Diabetes Care 2012, 35:181-188.
48. Shabir S., Jham S., Harper L., et al. Validity of glycated haemoglobin to diagnose new onset diabetes after transplantation. Transpl Int 2013, 26:315-321.
49. Chapman J.R. Chronic calcineurin inhibitor nephrotoxicity-lest we forget. Am J Transplant 2011, 11:693-697.
50. Sambol N.C., Chiang J., Lin E.T., et al. Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol 1995, 35(11):1094-1102.
51. Inzucchi S.E., Lipska K.J., Mayo H., et al. Metformin in patients with type 2 diabetes and kidney disease. A systematic review. JAMA 2014, 312:2668-2675.
52. Sharif A. Should metformin be our antiglycemic agent of choice post-transplantation?. Am J Transplant 2011, 11:1376-1381.
53. Kurian B., Joshi R., Helmuth A. Effectiveness and long-term safety of thiazolidinediones and metformin in renal transplant recipients. Endocr Pract 2008, 14(8):979-984.
54. Soliman A.R., Fathy A., Khashab S., et al. Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant. Exp Clin Transplant 2013, 11(6):494-498.
55. Jonsson A., Rydberg T., Sterner G., et al. Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. Eur J Clin Pharmacol 1998, 53(6):429-435.
56. Rosenkranz B., Profozic V., Metelko Z., et al. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia 1996, 39(12):1617-1624.
57. Asplund K., Wiholm B.E., Lundman B. Severe hypoglycaemia during treatment with glipizide. Diabet Med 1991, 8(8):726-731.
58. Holstein A., Beil W. Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions. Expert Opin Drug Metab Toxicol 2009, 5(3):225-241.
59. Holstein A., Plaschke A., Hammer C., et al. Hormonal counterregulation and consecutive glimepiride serum concentrations during severe hypoglycaemia associated with glimepiride therapy. Eur J Clin Pharmacol 2003, 59(10):747-754.
60. Balant L., Zahnd G., Gorgia A., et al. Pharmacokinetics of glipizide in man: influence of renal insufficiency. Diabetologia 1973, 9(Suppl):331-338.
61. Arjona Ferreira J.C., Marre M., Barzilai N., et al. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes Care 2013, 36(5):1067-1073.
62. Islam S.I., Masuda Q.N., Bolaji O.O., et al. Possible interaction between cyclosporine and glibenclamide in posttransplant diabetic patients. Ther Drug Monit 1996, 18(5):624-626.
63. Räkel A., Karelis A.D. New-onset diabetes after transplantation: risk factors and clinical impact. Diabetes Metab 2011, 37:1-14.
64. Sagedal S., Asberg A., Hartmann A., et al. Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients. Clin Transplant 1998, 12(6):553-556.
65. Tan A., Holmes H.M., Kuo Y.-F., et al. Coadministration of co-trimoxazole with sulfonylureas: hypoglycemia events and pattern of use. J Gerontol A Biol Sci Med Sci 2015, 70(2):247-254.
66. Inoue T., Shibahara N., Miyagawa K., et al. Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. Clin Nephrol 2003, 60(2):90-95.
67. Hasslacher C. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 2003, 26(3):886-891.
68. Türk T., Peitruck F., Dolff S., et al. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. Am J Transplant 2006, 6:842-846.
69. Kajosaari L.I., Niemi M., Neuvonen M., et al. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther 2005, 78:388-399.
70. Home P. Safety of PPAR agonists. Diabetes Care 2011, 34(Suppl 2):S215-S219.
71. Zhu Z.N., Jiang Y.F., Ding T. Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. Bone 2014, 68:115-123.
72. Budde K., Neumayer H.H., Frische L., et al. The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol 2003, 55(5):368-374.
73. Baldwin D., Duffin K.E. Rosiglitazone treatment of diabetes mellitus after solid organ transplantation. Transplantation 2004, 77(7):1009-1014.
74. Luther P., Baldwin D. Pioglitazone in the management of diabetes mellitus after transplantation. Am J Transplant 2004, 4:2136-2138.
75. Voytovich M.H., Simonsen C., Henssen T., et al. Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients. Nephrol Dial Transplant 2005, 20:413-418.
76. Lovshin J.A., Drucker D.J. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009, 5(5):262-269.
77. Scheen A.J. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010, 12:648-658.
78. Giorda C.B., Nada E., Tartaglino B. Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature. Endocrine 2014, 46:406-419.
79. Su H., Boulton D.W., Barros A., et al. Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in humans. Drug Metab Dispos 2012, 40:1345-1356.
80. Lane J.T., Odegaard D.E., Haire C.E., et al. Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation. Transplantation 2011, 92(10):e56-e57.
81. Boerner R.P., Miles C.D., Shivaswamy V. Efficacy and safety of sitagliptin for the treatment of new-onset diabetes after renal transplantation. Int J Endocrinol 2014, 2014:617638.
82. Halden T.A.S., Åsberg A., Vik K., et al. Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation. Nephrol Dial Transplant 2014, 29:926-933.
83. Sanyal D., Gupta S., Das P. A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting. Indian J Endocrinol Metab 2013, 17(Suppl 1):s203-s205.
84. Monami M., Dicembrini I., Mannucci E. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014, 16:48-56.
85. Clifton P. Do dipeptidyl IV (DPP-IV) inhibitors cause heart failure?. Clin Ther 2014, 36(12):2072-2079.
86. Udell J.A., Bhatt D.L., Braunwald E., for the SAVOR-TIMI 53 Steering Committee and Investigators, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 trial. Diabetes Care 2015, 38:696-705.
87. Linnebjerg H., Kothare P.A., Park S., et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007, 64(3):317-327.
88. Johansen O.E., Whitfield R. Exenatide may aggravate moderate diabetic renal impairment: a case report. Br J Clin Pharmacol 2008, 66(4):568-569.
89. Jacobsen L.V., Hindsberger C., Robson R., et al. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol 2009, 68(6):898-905.
90. Thomsen R.W., Pedersen L., Møller N., et al. Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study. Diabetes Care 2015, 38:1089-1098.
91. Pinelli N.R., Patel A., Salinitri F.D. Coadministration of liraglutide with tacrolimus in kidney transplant recipients: a case series. Diabetes Care 2013, 36:e171-e172.
92. Ghofaili K.A., Fung M., Ao Z., et al. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. Transplantation 2007, 83(1):24-28.
93. Froud T., Faradji R.N., Pileggi A., et al. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects. Transplantation 2008, 86(1):36-45.
94. Cariou B., Bernard C., Cantarovich D. Liraglutide in whole-pancreas transplant patients with impaired glucose homoeostasis: a case series. Diabetes Metab 2014, 41(3):252-257.
95. Yamout H., Perkovic V., Davies M., et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol 2014, 40:64-74.
96. Peters A.L., Buschur E.O., Buse J.B., et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015, 38(9):1687-1693.
97. Devineni D., Vaccaro N., Murphy J., et al. Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in health participants. Int J Clin Pharmacol Ther 2015, 53(2):115-128.
98. Muhlhauser I., Toth G., Sawicki P.T., et al. Severe hypoglycemia in type I diabetic patients with impaired kidney function. Diabetes Care 1991, 14(4):344-346.
99. Hasslacher C., Wittmann W. Severe hypoglycemia in diabetics with impaired renal function. Dtsch Med Wochenschr 2003, 128(6):253-256.
100. Baldwin D., Zander J., Munoz C., et al. A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency. Diabetes Care 2012, 35(10):1970-1974.
101. Keddis T., el Ters M., Rodrigo E., et al. Enhanced posttransplant management of patients with diabetes improves patient outcomes. Kidney Int 2014, 86:610-618.